Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 8/2014

01-08-2014 | Pediatric Rheumatology (S Ozen, Section Editor)

Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis

Authors: Rosa Bou, Estíbaliz Iglesias, Jordi Antón

Published in: Current Rheumatology Reports | Issue 8/2014

Login to get access

Abstract

Chronic anterior uveitis affects 10–30 % of patients with juvenile idiopathic arthritis (JIA) and is still a cause of blindness in childhood. In most patients it is asymptomatic, bilateral, and recurrent, so careful screening and early diagnosis are important to obtain the best long-term prognosis. The treatment of chronic uveitis associated with JIA is challenging. Initial treatment is based on topical steroids and mydriatic drops. Methotrexate is the most common first-line immunomodulatory drug used. For refractory patients, biologicals, mainly the anti-tumor-necrosis-factor (TNF) drugs adalimumab and infliximab, have been revealed to be effective and have changed the outcome for these patients. Collaboration between pediatric rheumatologists and ophthalmologists is important for the successful diagnosis and treatment of patients with uveitis associated with JIA.
Literature
1.
Carvounis PE, Herman DC, Cha S, Burke JP. Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol. 2006;244:281–90.PubMedCrossRef
2.
Petty RE, Smith JR, Rosenbaum JT. Arthritis and uveitis in children: A pediatric rheumatology perspective. Am J Ophthalmol. 2003;135:879–84.PubMedCrossRef
3.
Sabri K, Saurenmann RK, Silverman ED, Levin AV. Course, complications, and outcome of juvenile arthritis-related uveitis. J AAPOS. 2008;12:539–45.PubMedCrossRef
4.
Heiligenhaus A et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford). 2007;46(1015–1019).
5.
Cassidy J, Kivlin J, Lindsley C, Nocton J. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics. 2006;117:1843–5.PubMedCrossRef
6.
7.
Pelegrín L et al. Predictive Value of Selected Biomarkers, Polymorphisms, and Clinical Features for Oligoarticular Juvenile Idiopathic Arthritis-associated Uveitis. Ocul Immunol Inflamm. 2013. doi:10.​3109/​09273948.​2013.​841495.
8.
Nordal EB et al. Biomarkers of chronic uveitis in juvenile idiopathic arthritis: predictive value of antihistone antibodies and antinuclear antibodies. J Rheumatol. 2009;36:1737–43.PubMedCrossRef
9.
Angeles-Han ST, Yeh S, Vogler LB. Updates on the risk markers and outcomes of severe juvenile idiopathic arthritis-associated uveitis. Int J Clin Rheumtol. 2013(8).
10.
Kalinina Ayuso V et al. Intraocular biomarker identification in uveitis associated with juvenile idiopathic arthritis. Invest Ophthalmol Vis Sci. 2013;54:3709–20.PubMedCrossRef
11.••
Heiligenhaus A et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012;64:1365–72. Proposed core set of outcome measures for clinical trials in JIA-uveitis that have reached consensus by an international multidisciplinary working group of experts in uveitis.CrossRef
12.
Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117:1436–41.PubMedCentralPubMedCrossRef
13.
Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362–5.PubMed
14.
Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151:217–22.PubMedCrossRef
15.
Heiligenhaus A, Mingels A, Heinz C, Ganser G. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007;17:743–8.PubMed
16.•
Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology (Oxford). 2013;52:825–31. Meta-analysys on efficacy and safety of methotrexate in childhood uveitis, including 135 patients from 9 different studies.CrossRef
17.
Goebel JC et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95:209–13.PubMedCrossRef
18.••
Heiligenhaus A et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int. 2012;32:1121–33. German clinical gidelines for treatment of JIA-uveitis, including a therapeutic algorithm.PubMedCrossRef
19.
Teoh SC, Hogan AC, Dick AD, Lee RWJ. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146:752–60. 760.e1–3.PubMedCrossRef
20.
21.
Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115:1416–21. 1421.e1.PubMedCrossRef
22.
Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91:180–4.PubMedCentralPubMedCrossRef
23.
Chang PY et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond). 2011;25(427–35).
24.
Silverman E et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005;352:1655–66.PubMedCrossRef
25.
Molina C, Modesto C, Martín-Begué N, Arnal C. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32:1673–5.PubMedCrossRef
26.
Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860–4.e2.PubMedCrossRef
27.
Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308–14.PubMedCrossRef
28.
Richards JC, Tay-Kearney M-L, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005;33:461–8.CrossRef
29.
Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66:548–50.PubMedCentralPubMedCrossRef
30.•
Zannin ME et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74–9. Data from the National Italian Registryincludes 108 children with JIA-uveitis treated with infliximab or adalimumab.PubMedCrossRef
31.
Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358–64.PubMedCrossRef
32.
Sukumaran S, Marzan K, Shaham B, Reiff A. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012;2012(765380).
33.
Tambralli A et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40:1749–55.PubMedCrossRef
34.
Simonini G et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008;47(1510–4).
35.
Steenholdt C. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn’s disease. Dan Med J. 2013;60:B4616.PubMed
36.
Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gómez J. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17:456–9.PubMedCrossRef
37.
Kotaniemi K, Säilä H, Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol. 2011;5:1425–9.PubMedCentralPubMedCrossRef
38.
Dobner BC et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–8.PubMedCrossRef
39.
Vazquez-Cobian LB, Flynn T, Lehman TJA. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572–5.PubMedCrossRef
40.
41.
Tynjälä P et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(339–44).
42.•
García-De-Vicuña C et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediat Inflamm. 2013;2013:560632. Results from a multicentric study of 39 children with uveitis associated with JIA treated with adalimumab.
43.
Magli A et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013;251:1601–6.PubMedCrossRef
44.
Ramanan A. V et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15:14.PubMedCentralPubMedCrossRef
45.
Simonini G et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken). 2011;63(612–8).
46.
Doycheva D et al. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol. 2014;98:523–8.PubMedCrossRef
47.
Lovell DJ et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–20.PubMedCrossRef
48.
Smith JA et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23.PubMedCrossRef
49.
Saurenmann RK et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford). 2006;45(982–9).
50.
Leu JH et al. A36: Long-term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients With Polyarticular Juvenile Idiopathic Arthritis. Arthritis Rheumatol (Hoboken, NJ). 2014;66 Suppl 1:S55–6.CrossRef
51.
Brunner H et al. A148: a multi-center, double-blind, randomized-withdrawal trial of subcutaneous golimumab in pediatric patients with active polyarticular course juvenile idiopathic arthritis despite methotrexate therapy: week 48 results. Arthritis Rheumatol (Hoboken, NJ). 2014;66 Suppl 1:S191–2.CrossRef
52.
William M, Faez S, Papaliodis GN, Lobo A-M. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthal Inflamm Infect. 2012;2:231–3.CrossRef
53.
Cordero-Coma M, Salom D, Díaz-Llopis M, López-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011;118:1892.e3–4.CrossRef
54.
Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31:320–1.PubMed
55.
Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term Treatment with Golimumab for Severe Uveitis. Ocul Immunol Inflamm. 2013;22:90–5.PubMedCrossRef
56.
Tappeiner C, Heinz C, Ganser G, Heiligenhaus A. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol. 2012;39:1294–5.PubMedCrossRef
57.
Adán A, Mesquida M, Llorenç V, Modesto C. Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report. Graefes Arch Clin Exp Ophthalmol. 2013. doi:10.​1007/​s00417-013-2466-5.
58.
59.
Angeles-han S, Flynn T, Lehman T. Abatacept for Refractory Juvenile Idiopathic Arthritis-Associated Uveitis −− A Case Report. J Rheumatol. 2008(35).
60.
Elhai M, Deslandre CJ, Kahan A. Abatacept for refractory juvenile idiopathic arthritis-associated uveitis: two new cases. Comment on the article by Zulian et al. Arthritis Care Res (Hoboken). 2011;63:307–8. author reply 308.CrossRef
61.
Kenawy N et al. Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249:297–300.PubMedCrossRef
62.
Zulian F et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken). 2010;62(821–5).
63.
64.
Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford). 2011;50(1390–1394).
65.
Miserocchi E et al. Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev. 2011;11:35–9.PubMedCrossRef
Metadata
Title
Treatment of Uveitis Associated with Juvenile Idiopathic Arthritis
Authors
Rosa Bou
Estíbaliz Iglesias
Jordi Antón
Publication date
01-08-2014
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 8/2014
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0437-4

Other articles of this Issue 8/2014

Current Rheumatology Reports 8/2014 Go to the issue

Complementary and Alternative Medicine (SL Kolasinski, Section Editor)

Ayurvedic Medicine for Rheumatoid Arthritis

Pediatric Rheumatology (S Ozen, Section Editor)

Vaccination in Paediatric Rheumatology

Osteoporosis and Metabolic Bone Disease (KG Saag, Section Editor)

Use of DXA-Based Technology for Detection and Assessment of Risk of Vertebral Fracture in Rheumatology Practice

RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)

Vaccinations for Rheumatoid Arthritis

Spondyloarthritis (MA Khan, Section Editor)

Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice

Inflammatory Muscle Disease (RG Cooper, Section Editor)

Is Statin-Induced Myositis Part of the Polymyositis Disease Spectrum?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits